Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575604 | 1.00 | USP30 (0.58) | USP30HDAC4HDAC6DGAT2PARP1 | |
| SCHEMBL3546076 | 0.94 | HDAC4 (0.52) | USP30HDAC4HDAC6PARP1ALDH1A1 | |
| SCHEMBL12427424 | 0.92 | USP30 (0.52) | USP30HDAC4HDAC6PDE4APDE4B | |
| SCHEMBL12426326 | 0.86 | USP30 (0.46) | USP30PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12426777 | 0.86 | HTR4 (0.48) | USP30ALDH1A1 | |
| SCHEMBL12426778 | 0.86 | HTR4 (0.48) | USP30ALDH1A1 | |
| SCHEMBL13575607 | 0.83 | HTR4 (0.60) | USP30PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12426369 | 0.83 | NPSR1 (0.50) | USP30HDAC4ALDH1A1 | |
| SCHEMBL13575549 | 0.82 | KMT2A (0.46) | ALDH1A1 | |
| SCHEMBL13056742 | 0.82 | USP30 (0.66) | USP30HDAC4HDAC6PARP1ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | USP30 4195/4885HDAC4 2850/4885HDAC6 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.